Ibuprofen Inhibits Cystic Fibrosis Transmembrane Conductance Regulator-Mediated Cl- Secretion

Total Page:16

File Type:pdf, Size:1020Kb

Ibuprofen Inhibits Cystic Fibrosis Transmembrane Conductance Regulator-Mediated Cl- Secretion Ibuprofen inhibits cystic fibrosis transmembrane conductance regulator-mediated Cl- secretion. D C Devor, B D Schultz J Clin Invest. 1998;102(4):679-687. https://doi.org/10.1172/JCI2614. Research Article We evaluated the acute effects of ibuprofen and salicylic acid on cAMP-mediated Cl- secretion (Isc) in both colonic and airway epithelia. In T84 cells, ibuprofen inhibited the forskolin-dependent Isc in a concentration-dependent manner, having an apparent Ki of 142 microM. Salicylic acid inhibited Isc with an apparent Ki of 646 microM. We determined whether ibuprofen would also inhibit the forskolin-stimulated Isc in primary cultures of mouse trachea epithelia (MTE) and human bronchial epithelia (HBE). Similar to our results in T84 cells, ibuprofen (500 microM) inhibited the forskolin-induced Isc in MTEs and HBEs by 59+/-4% (n = 11) and 39+/-6% (n = 8), respectively. Nystatin was employed to selectively permeabilize the basolateral or apical membrane to determine the effect of ibuprofen on apical Cl- (ICl) and basolateral K+ (IK) currents after stimulation by forskolin. After forskolin stimulation, ibuprofen (500 microM) reduced both the ICl and IK; reducing ICl and IK by 60 and 15%, respectively. To determine whether this inhibition of ICl was due to the inhibition of CFTR, the effects of ibuprofen and salicylic acid on CFTR Cl- channels in excised, inside-out patches from L-cells were evaluated. Ibuprofen (300 microM) reduced CFTR Cl- current by 60+/-16% and this was explained by a short-lived block (approximately 1.2 ms) which causes an apparent reduction in single channel amplitude from 1.07+/-0.04 pA to […] Find the latest version: https://jci.me/2614/pdf Ibuprofen Inhibits Cystic Fibrosis Transmembrane Conductance Regulator–mediated Cl2 Secretion Daniel C. Devor and Bruce D. Schultz Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261 Abstract Introduction We evaluated the acute effects of ibuprofen and salicylic Cystic fibrosis (CF)1 is characterized by persistent Pseudomo- 2 acid on cAMP-mediated Cl secretion (Isc) in both colonic nas aeruginosa colonization of the conducting airways leading and airway epithelia. In T84 cells, ibuprofen inhibited the to the migration of inflammatory cells, including polymorpho- forskolin-dependent Isc in a concentration-dependent man- nuclear leukocytes (PMNs), into the airways of CF patients. It ner, having an apparent Ki of 142 mM. Salicylic acid inhib- is known that PMNs release the potent chemokinetic and ited Isc with an apparent Ki of 646 mM. We determined chemoattractant, leukotriene B during an inflammatory re- whether ibuprofen would also inhibit the forskolin-stimu- sponse (1) resulting in the further migration of inflammatory lated Isc in primary cultures of mouse trachea epithelia cells. Cromwell et al. (2) have demonstrated the existence of (MTE) and human bronchial epithelia (HBE). Similar to the leukotrienes in the sputum of CF patients. In addition to our results in T84 cells, ibuprofen (500 mM) inhibited the the migrating granulocytes themselves potentially causing forskolin-induced Isc in MTEs and HBEs by 5964% (n 5 damage to the airway epithelium, Metchnikoff first hypothe- 11) and 3966% (n 5 8), respectively. Nystatin was em- sized in 1887 that the products released from the invading ployed to selectively permeabilize the basolateral or apical granulocytes might be capable of injuring the host tissue as membrane to determine the effect of ibuprofen on apical well (3). More recently, the oxidative metabolites of arachi- 2 1 Cl (ICl) and basolateral K (IK) currents after stimulation donic acid and the inflammatory cell-derived proteases have by forskolin. After forskolin stimulation, ibuprofen (500 been implicated in the destruction and shedding of the airway mM) reduced both the ICl and IK; reducing ICl and IK by 60 epithelia observed in CF (3–7). Based on these observations, it and 15%, respectively. To determine whether this inhibition has been proposed that anti-inflammatory drugs might be use- of ICl was due to the inhibition of CFTR, the effects of ibu- ful in CF therapy. The nonsteroidal anti-inflammatory drug profen and salicylic acid on CFTR Cl2 channels in excised, (NSAID) ibuprofen is known to inhibit 5-lipoxygenase and inside-out patches from L-cells were evaluated. Ibuprofen hence leukotriene formation (8) suggesting that ibuprofen (300 mM) reduced CFTR Cl2 current by 60616% and this may be useful in the treatment of CF. Ibuprofen was initially was explained by a short-lived block (z 1.2 ms) which shown to attenuate the inflammatory response to P. aerugi- causes an apparent reduction in single channel amplitude nosa challenge in both a mouse (9) and rat (10) model without from 1.0760.04 pA to 0.5960.04 pA (n 5 3). Similarly, sali- affecting the clearance or pulmonary burden of the pathogen. cylic acid (3 mM) reduced CFTR Cl2 current by 5068% These results led to a clinical trial in CF patients where it was with an apparent reduction in single channel amplitude shown that high-dose (50–100 mg/ml plasma) ibuprofen from 1.0860.03 pA to 0.4860.06 pA (n 5 4). Based on these slowed the annual rate of change in forced expiratory volume results, we conclude that the NSAIDs ibuprofen and sali- in one second (FEV1) in patients with mild lung disease while cylic acid inhibit cAMP-mediated Cl2 secretion in human having no apparent adverse effects (11). In a second clinical colonic and airway epithelia via a direct inhibition of CFTR trial to assess pharmacokinetics and cohort therapy experi- Cl2 channels as well as basolateral membrane K1 channels. ence, plasma ibuprofen concentrations as high as 150 mg/ml This may reduce their efficacy in conjunction with other were reported (12). therapeutic strategies designed to increase CFTR expres- While NSAIDs are widely used over-the-counter medica- sion and/or function in secretory epithelia. (J. Clin. Invest. tions, their use is known to result in intestinal inflammation 1998. 102:679–687.) Key words: CFTR • chloride secretion • and injury (13–15). This effect is believed to be caused by an intestine • airway • ibuprofen increased mucosal permeability (16). Paradoxically, it has been speculated that this is due to the inhibition of the cyclooxygen- ase-dependent oxidation of arachidonic acid resulting in the Address correspondence to Daniel C. Devor, Ph.D., Department of depletion of endogenous prostaglandins (13). In addition to Cell Biology and Physiology, S312 BST, 3500 Terrace Street, Univer- their effects on the cyclooxygenase- and lipoxygenase-depen- sity of Pittsburgh, Pittsburgh, PA 15261. Phone: 412-383-8755; FAX: dent oxidation of arachidonic acid, the NSAIDs are structur- 1 412-648-8330; E-mail: dd2 @pitt.edu B.D. Schultz’s current address 2 is Department of Anatomy and Physiology, Kansas State University, ally related to the known Cl channel blockers, diphenyl- 1600 Denison Avenue, VMS 228, Manhattan, KS 66506; E-mail: [email protected] 1. Abbreviations used in this paper: 293B, trans-6-cyano-4-(N-ethyl- Received for publication 22 December 1997 and accepted in re- sulphonyl-N-methylamino)-3-hydroxy-2,2-dimethyl-chromane; CF, cys- vised form 2 June 1998. tic fibrosis; CFTR, cystic fibrosis transmembrane conductance regula- tor; FEV1, forced expiratory volume in one second; HBE, human 2 J. Clin. Invest. bronchial epithelium; HPC, human placental collagen; ICl, Cl cur- 1 © The American Society for Clinical Investigation, Inc. rents; IK, K currents; Isc, short circuit current; MTE, murine tracheal 0021-9738/98/08/0679/09 $2.00 epithelium; NSAID, nonsteroidal anti-inflammatory drug; PDte, trans- Volume 102, Number 4, August 1998, 679–687 epithelial potential difference; PKA, protein kinase A; PMNs, poly- http://www.jci.org morphonuclear leukocytes. Ibuprofen Inhibits CFTR 679 amine-2-carboxylate and 5-nitro-2-(3-phenylpropylamino)- Sepra, Inc., Cedex, France) and an air interface at the apical mem- benzoate (17). Also, the NSAIDs, niflumic acid and flufenamic brane established. The media bathing the basolateral surface was acid are known inhibitors of the Ca21-dependent Cl2 channel changed every 48 h. Measurements of Isc were performed after z 10– in Xenopus oocytes (18). These results suggested that the 20 additional days in culture. structurally related NSAID ibuprofen may similarly affect ion Isc measurements. Costar transwell cell culture inserts were mounted in an Ussing chamber (Jim’s Instruments, Iowa City, IA) transport across epithelia. Thus, we determined the effect of 2 and the monolayers continuously short-circuited (University of Iowa, ibuprofen on Cl secretion in both human colonic and airway Department of Bioengineering, Iowa City, IA). Transepithelial resis- epithelia. We demonstrate that ibuprofen, at a pharmacologi- tance was measured by periodically applying a 5-mV pulse, and the 2 cally relevant concentration, inhibits cAMP-dependent Cl se- resistance calculated using Ohm’s law. The bath solution contained cretion across human colonic and airway epithelia and that this (in mM): 120 NaCl, 25 NaHCO3, 3.3 KH2PO4, 0.8 K2HPO4, 1.2 inhibition is due at least in part to the blocking of the cystic fi- MgCl2, 1.2 CaCl2, and 10 glucose. The pH of this solution was 7.4 2 brosis transmembrane conductance regulator (CFTR) Cl when gassed with a mixture of 95% O2–5% CO2 at 378C. The effects 2 channel. of forskolin, ibuprofen, and glibenclamide on apical membrane Cl currents (ICl) were assessed after permeabilization of the serosal membrane with nystatin (360 mg/ml), and the establishment of a mu- Methods cosa-to-serosa Cl2 concentration gradient. Serosal NaCl was replaced by equimolar Na-gluconate. Nystatin was added to the serosal mem- T84 cell culture. T84 cells were grown in DME and Ham’s F-12 (1:1) brane 15–30 min before the addition of drugs (20). Successful perme- supplemented with 15 mM Hepes, 14 mM NaHCO3, and 10% FBS.
Recommended publications
  • Colitis Caused by Non-Steroidal Anti-Inflammatory Drugs
    Postgrad Med J: first published as 10.1136/pgmj.62.730.773 on 1 August 1986. Downloaded from Postgraduate Medical Journal (1986) 62, 773-776 Colitis caused by non-steroidal anti-inflammatory drugs S. Ravi', A.C. Keat2 and E.C.B. Keat1 'Cuckfield Hospital, Cuckfield, West Sussex, and2Westminster Hospital, Horseferry Road, London SWIP2AP, UK. Summary: Four cases of acute proctocolitis associated with non-steroidal anti-inflammatory drug therapy are presented. The drugs implicated were flufenamic acid, mefenamic acid, naproxen and ibuprofen. After resolution of symptoms and signs of proctocolitis three of the four patients were subsequently rechallenged with the implicated drug: in each there was a rapid relapse. Introduction Ulcerative colitis is a disease of unknown aetiology Case reports with characteristic clinical features and a protracted course. A similar clinical picture, but running a shorter Case I and usually benign course, is occasionally seen follow- ing the administration of certain drugs. This was first A 77 year old woman was referred with intermittent noticed following the administration of antibiotics, bleeding per rectum for 6 months, associated for the often with pseudomembrane formation. Later, this last 2 months with bloody diarrhoea up to eight times was shown to be associated with infection by toxigenic daily. Previously, she had had troublesome symptoms Clostridium difficile. Until 1978, most cases were from osteoarthritis of her back and knees for which copyright. associated with treatment with clindamycin but since she had been prescribed flufenamic acid 200 mg thrice that time nearly all antibiotics have been implicated. daily. Her general health had remained good but she Other drugs capable of causing proctocolitis, though appeared pale and her haemoglobin was reduced to by different mechanisms, include phenindione (Keat & 8 g/dl.
    [Show full text]
  • IBUPROFEN Ibuprofen Film-Coated Tablet 200 Mg
    NEW ZEALAND CONSUMER MEDICINE INFORMATION IBUPROFEN Ibuprofen film-coated tablet 200 mg IBUPROFEN also relieves fever • asthma, wheezing or What is in this leaflet (high temperature). shortness of breath • swelling of the face, lips, Please read this leaflet carefully Although IBUPROFEN can relieve tongue which may cause before you start IBUPROFEN. the symptoms of pain and difficulty in swallowing or inflammation, it will not cure your breathing This leaflet answers some common condition. • hives, itching or skin rash. questions about IBUPROFEN. • stomach ache, fever, chills, IBUPROFEN contains the active nausea and vomiting It does not contain all the available ingredient ibuprofen. Ibuprofen • fainting information. It does not take the belongs to a group of medicines place of talking to your doctor or called non-steroidal anti- If you are allergic to aspirin or pharmacist. inflammatory drugs (or NSAIDs). NSAID medicines and take IBUPROFEN, these symptoms All medicines have risks and Your doctor may have prescribed may be severe. benefits. Your doctor has weighed this medicine for another reason. the risks of you taking IBUPROFEN Do not take IBUPROFEN if you against the benefits they expect it Ask your doctor if you have any are in your third trimester of will have for you. questions about why this pregnancy. medicine has been prescribed for It may affect your developing baby if If you have any concerns about you. you take it during this time. taking this medicine, ask your doctor or pharmacist. Many medicines used to treat Do not take IBUPROFEN if you headache, period pain and other have (or have previously) Keep this leaflet with the aches and pains contain aspirin or vomited blood or material that medicine.
    [Show full text]
  • (Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
    TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS).
    [Show full text]
  • Efficacy of Ketoprofen Vs. Ibuprofen and Diclofenac: a Systematic Review of the Literature and Meta-Analysis P
    Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis P. Sarzi-Puttini1, F. Atzeni1, L. Lanata2, M. Bagnasco2 1Rheumatology Unit, L. Sacco University Hospital, Milan, Italy; 2Medical Department, Dompé SpA, Milan, Italy. Abstract Objective The aim of this systematic review of the literature and meta-analysis of randomised controlled trials (RCTs) was to compare the efficacy of orally administered ketoprofen with that of ibuprofen and/or diclofenac. Methods The literature was systematically reviewed in accordance with the Cochrane Collaboration guidelines. The search was restricted to randomised clinical trials published in the Medline and Embase databases up to June 2011, and comparing the efficacy of oral ketoprofen (50–200 mg/day) with ibuprofen (600-1800 mg/day) or diclofenac (75–150 mg/day). Results A total of 13 RCTs involving 898 patients met the inclusion criteria: eight comparing ketoprofen with ibuprofen, and five comparing ketoprofen with diclofenac. The results of the meta-analysis showed a statistically significant difference in efficacy in favour of ketoprofen. The difference between ketoprofen and the pooled ibuprofen/diclofenac data was also statistically significant (0.459, 95% CI 0.33-0.58; p=0.00) at all point-estimates of the mean weighted size effect. Ketoprofen was significantly superior to both diclofenac (mean = 0.422; 95% CI 0.19-0.65; p=0.0007) and ibuprofen (mean = 0.475; 95% CI 0.32-0.62; p=0.0000) at all point-estimates. Heterogeneity for the analysed efficacy outcome was not statisically significant in any of the meta-analyses. Conclusion The efficacy of orally administered ketoprofen in relieving moderate-severe pain and improving functional status and general condition was significantly better than that of ibuprofen and/or diclofenac.
    [Show full text]
  • The Aryl Propionic Acid R-Flurbiprofen Selectively Induces P75ntr- Dependent Decreased Survival of Prostate Tumor Cells Emily J
    Research Article The Aryl Propionic Acid R-Flurbiprofen Selectively Induces p75NTR- Dependent Decreased Survival of Prostate Tumor Cells Emily J. Quann,1 Fatima Khwaja,1 Kenton H. Zavitz,3 and Daniel Djakiew1,2 1Department of Biochemistry and Molecular & Cellular Biology and the 2Vincent T. Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Columbia, and 3Myriad Pharmaceuticals Inc., Salt Lake City, Utah Abstract oxygenase (COX), the enzyme which catalyzes the conversion of Epidemiologic studies show that patients chronically consum- arachidonic acid to prostaglandins. Two isoforms of COX exist; ing nonsteroidal anti-inflammatory drugs (NSAID) for arthri- COX-1 is a housekeeping gene that is constitutively expressed at tis exhibit a reduced incidence of prostate cancer. In addition, low levels in most cells types, whereas COX-2 is highly inducible in some NSAIDs show anticancer activity in vitro.NSAIDs response to cytokines, hormones, and growth factors. COX-2 seems exert their anti-inflammatory effects by inhibiting cyclo- to play a significant role in the promotion of colon cancer with 50% oxygenase (COX) activity; however,evidence suggests that of precancerous adenomatous polyps and 85% of colon carcinomas COX-independent mechanisms mediate decreased prostate exhibiting COX-2 overexpression (9). However, the data pertaining cancer cell survival. Hence,we examined the effect of selected to the role of COX-2 in prostate cancer are less conclusive. Although some studies show overexpression, others show expres- aryl propionic acid NSAIDs and structurally related com- pounds on the decreased survival of prostate cancer cell lines sion is low or absent relative to normal tissue (10–14).
    [Show full text]
  • Central Nervous System Toxicity of Mefenamic Acid
    Central Nervous System toxicity of mefenamic acid overdose compared to other NSAIDs: an analysis of cases reported to the United Kingdom National Poisons Information Service. Running header: CNS toxicity of mefenamic acid A Kamour1, S Crichton2, G Cooper3, DJ Lupton4, M Eddleston4,5, JA Vale6, JP Thompson 3, SHL Thomas1,7 1National Poisons Information Service, Newcastle Unit, Newcastle upon Tyne Hospitals NHS Foundation Trust, Wolfson Unit, Claremont Place, Newcastle upon Tyne, NE2 4HH. 2Department of Primary Care and Public Health, King's College London, Capital House, London, SE1 3QD 3National Poisons Information Service, Cardiff Unit, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX. 4National Poisons Information Service, Edinburgh Unit, Royal Infirmary of Edinburgh, 51 Little France Crescent, Old Dalkeith Road, Edinburgh EH16 4SA. 5Pharmacology, Toxicology and Therapeutics, University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK. 6National Poisons Information Service, Birmingham Unit, City Hospital, Dudley Road, Birmingham B18 7QH. 7Medical Toxicology Centre, Institute of Cellular Medicine, Wolfson Building, Newcastle University, Newcastle NE2 4HH. Address for correspondence: Dr Ashraf Kamour, Acute Medical Unit, North Manchester General Hospital Delaunays Road, Crumpsall, Manchester, M8 5RB, UK. Tel: +44 (0)161 918 4673 This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bcp.13169 This article is protected by copyright. All rights reserved. Fax: +44 (0)161 604 5323 Email: [email protected] Keywords: Mefenamic acid, non-steroidal anti-inflammatory drug, overdose, poisoning, CNS toxicity, convulsions.
    [Show full text]
  • PATIENT FACT SHEET (Nonsteroidal Anti-Inflammatory Drugs)
    NSAIDs PATIENT FACT SHEET (Nonsteroidal anti-inflammatory drugs) NSAIDs (Nonsteroidal anti-inflammatory drugs) are play a role in pain and inflammation. NSAIDs also can some of the most commonly used pain medicines decrease inflammation, such as fever, swelling and in adults. They are also a common treatment for redness. Traditional NSAIDs include aspirin, ibuprofen chronic (long-term) health problems, such as arthritis (Advil, Motrin, etc.), naproxen (e.g., Aleve) and many (rheumatoid arthritis, osteoarthritis and others) and other generic and brand name drugs. Celecoxib lupus. NSAIDs block proteins, called enzymes, in the (Celebrex) belongs to a newer class of NSAIDs, which WHAT IS IT? body that help make prostaglandins. Prostaglandins doctors call a “COX-2 inhibitor,” and is designed to are a group of naturally occurring fatty acids that avoid upset stomach. Each NSAID has its own dose (strength) and interval improvement of swelling. Do not mix an over-the-counter for how often to take the drug. The dosage size of NSAID with a prescribed NSAID or take more than the over-the-counter medicine (those sold without a doctor’s recommended dose of the NSAID. Doing so could increase prescription) is often less than prescription versions of the your chance of side effects. Doctors have long warned not same medicine. NSAIDs start to work quickly, most often to give aspirin to children under age 12, but teens with a within a few hours. How fast they take affect depends virus also should avoid drugs containing aspirin. There is a HOW TO on the intended effect. Pain control tends to occur risk of Reye’s syndrome, a rare but deadly illness that can TAKE IT much quicker than anti-inflammatory effects, such as affect the brain and liver.
    [Show full text]
  • Myth: Parenteral Ketorolac Provides More Effective Analgesia Than Oral Ibuprofen
    EDUCATION • ÉDUCATION MEDICAL MYTHOLOGY Myth: Parenteral ketorolac provides more effective analgesia than oral ibuprofen Sanjay Arora, MD;* Jonathan G. Wagner, BA;† Mel Herbert, MD, MB BS, BMedSci‡ Introduction Results Acute pain is an extremely common presenting symptom to In 1994, Wright and associates evaluated the effectiveness the emergency department (ED), making it imperative that of a single dose of 800 mg of oral ibuprofen (n = 95) ver- emergency physicians provide adequate, safe and cost-ef- sus 60 mg of IM ketorolac (n = 70). This was a retrospec- fective analgesia. Nonsteroidal anti-inflammatory drugs tive analysis of data collected during a prior prospective (NSAIDs) are often first-line treatments for moderate to se- survey of pain management efficacy, in patients presenting vere pain. Physicians can choose between intramuscular to the ED with acute pain due to a large variety of causes.2 (IM) or intravenous (IV) ketorolac and an oral NSAID. The Using the 100-mm visual analog pain scale (VAS) they mechanism of action (reversible inhibition of prostaglandin found a mean score reduction of 34 in the ibuprofen group synthesis at the level of cyclooxygenase) is identical irre- and 35 in the ketorolac group. They concluded that the 2 spective of the route the medication is given.1 Despite the have almost identical efficacy in those presenting with similar pharmacodynamics, many physicians believe that acute pain of varied sources, and that unless oral adminis- parenteral ketorolac is more efficacious, despite a greater tration
    [Show full text]
  • FLURBIPROFEN - Flurbiprofen Tablet, Film Coated STAT RX USA LLC
    FLURBIPROFEN - flurbiprofen tablet, film coated STAT RX USA LLC ---------- DESCRIPTION Flurbiprofen is a member of the phenylalkanoic acid derivative group of non-steroidal anti-inflammatory drugs. Flurbiprofen tablets are beige, round, film-coated tablets for oral administration. Flurbiprofen is a racemic mixture of (+)S- and (-)R-enantiomers. Flurbiprofen, USP is a white or slightly yellow crystalline powder. It is slightly soluble in water at pH 7.0 and readily soluble in most polar solvents. The chemical name is [1,1'-biphenyl]-4-acetic acid, 2-fluoro-alpha-methyl-, (±)-. The molecular weight is 244.26. Its molecular formula is C15H13FO2 and it has the following structural formula FLURBIPROFEN 100MG STRUCTURE IMAGE Each tablet, for oral administration, contains 50 mg or 100 mg flurbiprofen, USP. Inactive ingredients are colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose (anhydrous), magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, sodium lauryl sulfate, titanium dioxide, triacetin, yellow iron oxide and black iron oxide. CLINICAL PHARMACOLOGYPharmacodynamics Flurbiprofen is a non-steroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of flurbiprofen, like that of other non- steroidal anti-inflammatory drugs, is not completely understood but may be related to prostaglandin synthetase inhibition. PharmacokineticsAbsorption The mean oral bioavailability of flurbiprofen 100 mg tablets is 96% relative to an oral solution. Flurbiprofen is rapidly and non-stereoselectively absorbed with peak plasma concentrations occurring at about 2 hours (see Table 1). Administration of flurbiprofen with either food or antacids may alter the rate but not the extent of flurbiprofen absorption. Ranitidine has been shown to have no effect on either the rate or extent of flurbiprofen absorption.
    [Show full text]
  • Motrin® Ibuprofen Tablets, USP
    Effective Date: 01/20/2007 Motrin® Ibuprofen Tablets, USP Cardiovascular Risk • NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS). • MOTRIN tablets are contraindicated for treatment of peri- operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). Gastrointestinal Risk • NSAIDs cause an increased risk of serious gastrointestinal adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). DESCRIPTION MOTRIN tablets contain the active ingredient ibuprofen, which is (±) - 2 - (p - isobutylphenyl) propionic acid. Ibuprofen is a white powder with a melting point of 74-77° C and is very slightly soluble in water (<1 mg/mL) and readily soluble in organic solvents such as ethanol and acetone. The structural formula is represented below: MOTRIN tablets, a nonsteroidal anti-inflammatory drug (NSAID), is available in 400 mg, 600 mg, and 800 mg tablets for oral administration. Inactive ingredients: carnauba wax, colloidal silicon dioxide, croscarmellose sodium, hypromellose, lactose, magnesium stearate, microcrystalline cellulose, propylene glycol, titanium
    [Show full text]
  • Selectivity of Nonsteroidal Antiinflammatory Drugs As Inhibitors
    Proc. Natl. Acad. Sci. USA Vol. 90, pp. 11693-11697, December 1994 Pharmacology Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase (cytokines/arachidonic add/prostanoids/inflammation/mitogen/aspirin-like drugs) JANE A. MITCHELL*, PRAVIT AKARASEREENONT, CHRISTOPH THIEMERMANN, RODERICK J. FLOWER, AND JOHN R. VANE The William Harvey Research Institute, St. Bartholomew's Hospital Medical College, Charterhouse Square, London EClM 6BQ, United Kingdom Contributed by John R. Vane, September 9, 1993 ABSTRACT Constitutive cyclooxygenase (COX-1; pros- COX-2 may well explain their therapeutic utility as antiin- taglandin-endoperoxide synthase, EC 1.14.99.1) is present in flammatory drugs, whereas inhibition of COX-1 may explain cells under physiological conditions, whereas COX-2 is induced their unwanted side effects, such as gastric and renal damage. by some cytokines, mitogens, and endotoxin presumably in After establishing that bovine aortic endothelial cells in pathological conditions, such as inflammation. Therefore, we culture contain COX-1 and that endotoxin-activated J774.2 have assessed the relative inhibitory effects of some nonsteroi- macrophages contain COX-2, we have investigated the in- dal antiinflammatory drugs on the activities of COX-1 (in hibitory effects of some NSAIDs on the activity of COX-1 bovine aortic endothelial cells) and COX-2 (in endotoxin- and COX-2 in whole cells and broken cells and in purified activated J774.2 macrophages) in intact ceils, broken cells, and enzyme preparations. Our results show that NSAIDs have purified enzyme preparations (COX-1 in sheep seminal vesi- different profiles ofinhibition ofCOX-1 and COX-2 in a range cles; COX-2 in sheep placenta).
    [Show full text]
  • Four New Anti-Inflammatory Drugs: Responses and Variations
    1048 BRITISH MEDICAL JOURNAL 1 MAY 1976 The final place of labetalol for hypertension must await the 3 Frohlich, E D, et al, Circulation, 1968, 37, 417. results of forthcoming comparative studies. Our data indicate 4 Hansson, L, et al, Klinische Wochenschrift, 1972, 50, 364. s Somer, T, Luomanmaki, K, and Frick, M H, Acta Medica Scandinavica, Br Med J: first published as 10.1136/bmj.1.6017.1048 on 1 May 1976. Downloaded from that it is well suited for treating mild and moderate hypertension, 1974, suppl No 554, p 33. in which we restored the blood pressure to normal in 75o, of 6 Furberg, C, et al, Acta Medica Scandinavica, 1969, 186, 447. patients with a dose of 200 mg thrice daily. Evident advantages 7 Lydtin, H, et al, American HeartJournal, 1972, 83, 589. substances include safer use in patients 8 Prichard, B N C, et al, British Heart Journal, 1970, 32, 236. over pure beta-blocking 9 Hansson, L, et al, Acta Medica Scandinavica, 1974, 196, 27. with initial bradycardia; in patients with atrioventricular con- 10 Tarazi, R C, and Dustan, H P, American Journal of Cardiology, 1972, 29, duction disturbances; and in asthmatics, who do not exhibit 633. bronchoconstriction when on labetalol.18 1 Farmer, J B, et al, British Journal of Pharmacology, 1972, 45, 660. 12 Kennedy, I, and Levy, G P, BritishJournal of Pharmacology, 1975, 53, 585. 13 Richards, D A, et al, British3Journal of Clinical Pharmacology, 1974, 1, 505. 14 Collier, J G, et al, British Journal of Pharmacology, 1972, 44, 286. References 15 Katila, M, and Frick, M H, InternationalJouirnal of Clinical Pharmacology, Therapy and Toxicology, 1970, 4, 111.
    [Show full text]